Cargando…
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
Coronary artery disease in the transplanted heart, also known as cardiac allograft vasculopathy (CAV), is one of the major causes of mortality late after transplantation. It affects up to 50% of all heart transplant recipients within 5 years of surgery. The mechanisms of CAV are multifactorial and i...
Autor principal: | Kobashigawa, Jon |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59623/ https://www.ncbi.nlm.nih.gov/pubmed/11714434 http://dx.doi.org/10.1186/cvm-1-3-166 |
Ejemplares similares
-
The role of everolimus in treatment of cardiac allograft vasculopathy
por: Watanabe, Tetsu
Publicado: (2013) -
The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019) -
Risk factors of cardiac allograft vasculopathy
por: Szyguła-Jurkiewicz, Bożena, et al.
Publicado: (2015) -
Early Cardiac Allograft Vasculopathy: Are the Viruses to Blame?
por: Aggarwal, Ashim, et al.
Publicado: (2012) -
Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis
por: Skorić, Boško, et al.
Publicado: (2014)